NMPA’s 2026 Post-Market Vigilance Framework: Essential Compliance Guide for Overseas Medical Device Manufacturers May 25, 2026
11 Class III Devices and 66 IVDs to be Newly Exempted from Clinical Trial; Feedback until May 29 May 19, 2026
